Clinical-stage biotechnology company TME Pharma N.V. (Euronext Growth Paris:ALTME) announced on Thursday that it has received a EUR2.4m grant from the German Federal Ministry of Education and Research (BMBF) to support its Phase 2 clinical trial for NOX-A12, a potential treatment for glioblastoma.
This non-dilutive funding, combined with other grants totalling approximately EUR5m, will support the randomised controlled study evaluating NOX-A12 in combination with bevacizumab.
The Phase 2 trial, approved by the US Food and Drug Administration (FDA) and the German regulator, aims to optimise the dosing regimen and assess the efficacy of the combination therapy.
Correction - DeepHealth expands FDA clearance for SmartMammo Dx with GE HealthCare integration
DeepHealth expands FDA clearance for SmartMammo Dx with GE HealthCare integration
Formosa Pharmaceuticals licenses eye drops for Switzerland and Liechtenstein
Galderma reports Phase III data for nemolizumab in prurigo nodularis published in JAMA Dermatology
AOP Health's Rapiblyk approved by FDA for atrial fibrillation and atrial flutter
PTC Therapeutics to sell Priority Review Voucher for USD150m
Novartis' Kisqali approved in EU for broader population of high-risk early breast cancer patients
Merck reports positive Phase 3 ZENITH results for WINREVAIR in PAH treatment
Alnylam's sNDA for vutrisiran accepted by FDA; PDUFA date set for March 2025
GSK plc announces US FDA acceptance of review for Blenrep combinations in multiple myeloma
Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical announce progress in BH3120 clinical trial
Johnson & Johnson seeks FDA approval for subcutaneous TREMFYA